In this engaging discussion, Harry Erba, a professor at Duke University, shares insights on prolonging remission in acute myeloid leukemia (AML). Joined by Farhad Ravandi from MD Anderson, they delve into the significance of measurable residual disease (MRD) assays in customizing post-remission therapies. Thomas Cluzeau from Central University Hospital of Nice emphasizes the role of allogeneic stem cell transplantation and innovative maintenance therapies. The trio explores new treatments like CPX351 and the essential nature of ongoing clinical trials to improve patient survival.

Guests Thomas Cluzeau, Naval Daver, and Andrew Wei discuss the latest AML therapies, including the use of CPX351 as a potential cure for certain patients, the safety and efficacy of Magrola MAB in combination with azacitidine, the high response rates and safety profile of treatment for TP53 AML patients, and updates on Venetoclax plus low dose Cytarabine study in previously untreated older AML patients.